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 2.1. Abstract  
 
Pharmacotherapy of schizophrenia is associated with the stressful side effects. Muscle rigidity 
causes distress, discomfort and poor compliance. The aim of the study was to determine the 
relationship between plasma hormones (cortisol and prolactin /PRL/) and muscle rigidity in 
female schizophrenic patients treated with olanzapine or fluphenazine.  In a randomized, double-
blind 22-weeks study, 12 patients were treated with olanzapine (5-20 mg/day) and 10 patients 
received fluphenazine (6-21 mg/day). Treatment with olanzapine moderately decreased, while 
treatment with fluphenazine significantly increased plasma cortisol levels and muscle rigidity. 
The marked and moderate increase in plasma PRL levels were found in patients treated with 
fluphenazine and olanzapine, respectively. The results suggested that olanzapine induced 
moderate neuroendocrine effects and a reduction in rigidity as compared to fluphenazine 
treatment.  
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3.1. Introduction   
The pharmacotherapy of schizophrenia (Kane, 2001) is often associated with the extrapyramidal 
side effects (EPS) related to the blockade of dopamine D2 receptors in the basal ganglia (Crocker 
and Hemsley, 2001) and disturbance of dopaminergic and serotonergic/cholinergic systems. Muscle 
rigidity and other EPS cause distress, discomfort and poor compliance. Stress hormones prolactin 
(PRL) and cortisol are related to distress response (Jakovljevic et al., 1991; Tandon and Halbreich, 
2003). Olanzapine is an atypical antipsychotic of the thienobenzodiazepine class. New 
antipsychotics induce a moderate blockade of D2 receptors and generate a more subtle functional 
motor impairment and better treatment response (Putzhammer et al., 2005) than conventional 
antipsychotics, like fluphenazine. Fluphenazine reduces psychotic symptoms, but induces different 
side effects (Mortimer, 1994) due to its action achieved via D1 and D2 receptors (Coirini et al., 1997; 
Meltzer and Nesh, 1991).  
Since olanzapine and fluphenazine differ in their side effects profile and clinical efficacy 
(Dossenbach et al., 2004), our hypothesis was that olanzapine and fluphenazine would differently 
affect plasma cortisol, PRL and muscle rigidity. The aim of the present study was to determine, in 
the smaller group of female schizophrenic patients extracted from the previous multicentric double 
blind study (Dossenbach et al., 2004), the effects of olanzapine or fluphenazine on plasma PRL and 
cortisol levels, and muscle rigidity after long term (22-weeks) treatment. 
 
3.2. Subjects and methods 
In a randomized, double blind 22-week study, 22 female schizophrenic (DSM-IV criteria; 
American Psychiatric Association, 1994) patients (mean age ± SD, 33.2 ± 8.8 years) were treated 
with either olanzapine (N=12) or fluphenazine (N=10) in the Clinical Hospital Centre Zagreb. 
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Patients were part of the group included in a multicentric clinical trial (Dossenbach et al., 2004). 
The Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) was used to evaluate 
schizophrenic symptoms, and baseline total PANSS scores were 96.9 ±15.4 for fluphenazine, and 
107.7 ± 19.1 for olanzapine-treated patients, respectively.  
On admission, 12 patients (5 assigned to olanzapine and 7 to fluphenazine) had been drug 
free for about 1 year. None of the patients received depot neuroleptics. Other patients were 
medicated with haloperidol and clozapine, with a similar distribution of previous haloperidol (15 
mg/day) users among two treatment groups. Samples were taken after a wash-out of at least 7 
days before and after 22-weeks of treatment with olanzapine (dose 5-20 mg; mean 12.8 ± 2.8 
mg/day) or fluphenazine (6-21 mg; mean 10.5 ± 2.5 mg/day). Concomitant psychoactive 
medications were not allowed, except benzodiazepines for sleep disturbances and/or severe 
anxiety. Each group consisted of one menopausal patient. In the pre-menopausal patients blood 
samples were collected between 1st and 7th day of the menstrual cycle. All participants provided 
written informed consent prior to the study entry. 
Cortisol (nmol/L) and PRL (ng/ml) were measured in plasma by a radioimmunoassay and 
immunoradiometric assay (Diagnostic Products Corporation, USA) with detection limit of 5.5 
nmol/L and 0.1 ng/ml, and intra- and inter-assay coefficients of variation 4.7% and 5.2% for 
cortisol and 1.6% and 2.8% for PRL, respectively. Clinical ratings and biochemical measures 
were made blind to each other.  
Rigidity assessment was performed using computerized instrumental measurement by 
elbow device “Tonometre” (Relja et al., 1996). A patient was comfortable seated in a chair, with 
the tested forearm supported horizontally on an arm board of the tonometre. The rigidity 
registration was carried out through 20 consecutive cycles (flexion and extension). The first 10 
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measurements were preparatory, aimed to achieve maximal relaxation of the patients. The 
second 10 cycles were transmitted and evaluated, with the results expressed in Newton meters 
(Nm), as mean ± SD of 10 measurements (Relja et al., 1996).  
Statistical evaluation of the results, expressed as mean ± SD, was done using one-way 
analysis of variance (ANOVA), two-way ANOVA, repeated measures analysis of variance 
(RMANOVA) and Newman Keuls’ test, Pearson’s coefficient of correlation, and Student t-test (for 
comparisons between two groups). The significance level was p<0.05. The statistical package used 
was SigmaStat 2.0. 
 
3. 3. Results  
Before treatment plasma cortisol levels did not differ significantly (p>0.05) among schizophrenic 
patients (Fig 1A). After 22-weeks of treatment (Fig. 1A), plasma cortisol levels differed 
significantly (F=8.85; df=4,61; p<0.001), with a significant (p<0.05) fluphenazine-induced 
increase (24.5%), as compared to olanzapine-induced decrease (15%) of cortisol levels. A 
significant effect of olanzapine or fluphenazine treatment (F=5.47; df =1,43; p<0.025), and a 
significant interaction between treatment and time (22-weeks vs. baseline) (F=4.56; df =1,43; 
p<0.039) on plasma cortisol levels was found (two-way ANOVA). 
Treatment with either olanzapine or fluphenazine significantly (F=16.5; df=3,45; 
p<0.001) increased plasma PRL levels (Fig. 2), with a significant (p<0.05) fluphenazine (87%) or 
olanzapine (35%) induced increase of plasma PRL levels when compared to baseline values. 
Plasma PRL levels were significantly higher (p<0.05) after fluphenazine than after olanzapine 
treatment (Fig. 2). A significant (F=12.94; df =1,43; p<0.0001) effect of treatment (olanzapine vs. 
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fluphenazine), and time (F=12.05; df =1,43; p<0.001) (22-weeks vs. baseline), on plasma PRL 
levels was found (two-way ANOVA). 
Baseline mean rigidity values in schizophrenic patients (1.71 ± 0.84 Nm) were slightly 
higher than those in healthy control (1.58 ± 0.96 Nm), (Relja et al. 1996). Treatment with 
olanzapine significantly (F= 7.53, df= 1,11; p = 0.019) decreased, while treatment with 
fluphenazine significantly (F= 7.08, df= 1,9; p= 0.026) increased the rigidity values (Fig. 1B), 
respectively (RMANOVA).  
Although olanzapine or fluphenazine treatment affected significantly and in an opposite 
manner the rigidity and plasma cortisol values in schizophrenic patients, there was no significant 
(p>0.05) correlation between muscle rigidity and plasma cortisol before (r = 0.25 and r= -0.16) or 
after (r= 0.35 and r= -0.27) treatment with fluphenazine or olanzapine, respectively.  
Age of the patients did not differ significantly (t=1.68; df=20; p=0.11, Student’s t-test) 
between those treated with olanzapine (29.5 ± 8.4, range 20-46 years) or fluphenazine (35.6 ± 
8.3, range 20-52 years). No significant correlation between age and plasma cortisol (r = -0.15; 
p=0.50), or age and plasma PRL (r=-0.30; p=0.17) levels was found.   
 
3. 4. Discussion 
The results of the present study showed the opposite effects of treatment with olanzapine and 
fluphenazine on plasma cortisol values and muscle rigidity, indicating that schizophrenic patients 
receiving olanzapine might have been exposed to a smaller amount of EPS-related distress than 
those treated with fluphenazine. The improvement in the muscle rigidity confirms the favorable 
profile of olanzapine in the treatment of schizophrenia (Tandon and Halbreich, 2003; Dossenbach 
et al., 2004). The opposite neuroendocrine effects of olanzapine and fluphenazine on plasma 
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cortisol levels in schizophrenic patients (present study), and the “normalization” of the HPA axis 
hyperactivity (Muck-Seler et al., 1999; Ryan et al., 2004), support the assumption that the 
suppression of the HPA axis hyperactivity is related to the treatment response (Tandon and 
Halbreich, 2003). 
The HPA axis activity might be influenced by different factors such as gender, stress, 
psychiatric comorbidity, previous medication, older age, or different phases of menstrual cycle. 
To exclude these factors, only female patients, part of the bigger, large multicentric study 
(Dossenbach et al., 2004) were included, matched for previous medication and the level of stress. 
Patients with comorbid diagnoses and those who received depot neuroleptics were excluded. No 
correlation between age and plasma cortisol levels was found in the present and previous studies 
(Muck-Seler et al., 1999; Seeman and Robbins, 1994). To avoid the possible influence of 
menstrual phases on the HPA activity (Leibenluft et al., 1994), patients were sampled in the 
follicular phase, and previously we have shown that pre- or post-menopausal status did not affect 
significantly plasma cortisol levels in schizophrenic patients (Muck-Seler et al., 2004).  
Hyperprolactinemia is a common side effect of typical antipsychotics (Halbreich et al., 
2003; Petty, 1999), while atypical antipsychotics especially olanzapine, are PRL-sparing drugs 
(Dickson and Glazer, 1999). In our study fluphenazine induced more pronounced PRL increase 
than olanzapine.  If a magnitude of the hyperprolactinemia may be used as a biological marker 
for the therapeutic effects of antipsychotic drugs (Halbreich et al., 2003), higher PRL levels 
found after fluphenazine than after olanzapine treatment are in line with the better treatment 
response in olanzapine than in fluphenazine treated schizophrenic patients (Dossenbach et al., 
2004). 
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The limitation of the study is a lack of multiple sampling of plasma cortisol and PRL 
levels, while its advantage lays in a randomized, comparative and double blind 22-weeks design. 
However, our results on the slight decrease in cortisol and moderate increase in PRL levels after 
olanzapine treatment agree with the nocturnal hormone profile in schizophrenic patients treated 
with olanzapine (Mann et al., 2006). On the other hand, olanzapine treatment did not affect 
significantly plasma cortisol or PRL levels in healthy controls sampled at a similar time-point 
(i.e. at  9.00  a.m., Cohrs et al., 2006). This difference in the results between healthy and 
schizophrenic subjects is presumably due to the abnormal HPA axis in schizophrenia (Tandon et 
al., 1991; Muck-Seler et al., 1999; Mann et al., 2006). 
The different neuroendocrine effects of the two antipsychotics are due to their different 
pharmacological profile. Olanzapine is a potent antagonist of 5-HT2A and D2 receptors, with 
higher affinity for 5-HT2A than for D2 receptors (Bymaster et al., 1996; Richelson and Souder, 
2000; Nyberg et al., 1997). Its beneficial effect is related to its combined 5-HT2A/5-HT2C and D2 
blocking properties, which results in the suppression of PRL secretion (Markianos et al., 2001), 
while fluphenazine blocks D2 receptors which increase PRL release (Coirini et al., 1997).  
In conclusion, our results showed that atypical antipsychotic olanzapine had a favorable 
effect on the muscle rigidity and better neuroendocrine profile than conventional neuroleptic 
fluphenazine.  
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Legends for figures  
 
 
Fig 1. Plasma cortisol levels (nmol/L) (A) and muscle rigidity (Nm) (B) in schizophrenic patients 
before and after treatment with olanzapine or fluphenazine. Each column represents mean ± SD. 
Number of subjects is given in brackets. * p<0.05 vs. olanzapine after treatment, **p<0.05 vs. 
olanzapine before treatment (ANOVA followed by Newman-Keuls’ test).  
 
 
Fig 2. PRL (ng/ml) levels in schizophrenic patients before and after treatment with olanzapine or 
fluphenazine. Each column represents mean ± SD. Number of subjects is given in brackets.  * 
p<0.05 vs. fluphenazine before treatment; ** p<0.05 vs. olanzapine after treatment (ANOVA 
followed by Newman-Keuls’ test).  
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